{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:23:42Z","timestamp":1790796222483,"version":"4.1.0"},"reference-count":12,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,6,18]],"date-time":"2013-06-18T00:00:00Z","timestamp":1371513600000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatrics International"],"published-print":{"date-parts":[[2013,6]]},"abstract":"Abstract<\/jats:title>Reported herein is a case of relapse of nephrotic syndrome (NS<\/jats:styled-content>) after intravitreal injection of beva<\/jats:styled-content>cizumab, a monoclonal antibody that binds to vascular endothelial growth factor (VEGF)<\/jats:styled-content>, in a 16\u2010year\u2010old girl. She had a diagnosis of steroid\u2010dependent NS<\/jats:styled-content> and had been treated with prednisolone, and remained in remission. The patient had had visus brevior 10 years previously, and was diagnosed with severe myopic choroidal neovascularization (mCNV<\/jats:styled-content>). Intravitreal bevacizumab was given for mCNV<\/jats:styled-content>. At 9 days after intravitreal injection of bevacizumab, proteinuria was positive. The patient had relapse of NS<\/jats:styled-content> caused by bevacizumab, and steroid pulse therapy was then given and the proteinuria resolved. It is necessary to take particular care to prevent NS<\/jats:styled-content> relapses in patients with mCNV<\/jats:styled-content> treated with intravitreal bevacizumab.<\/jats:p>","DOI":"10.1111\/ped.12017","type":"journal-article","created":{"date-parts":[[2013,6,19]],"date-time":"2013-06-19T03:25:44Z","timestamp":1371612344000},"source":"Crossref","is-referenced-by-count":25,"title":["Relapse of minimal change nephrotic syndrome after intravitreal bevacizumab"],"prefix":"10.1111","volume":"55","author":[{"given":"Tomoko","family":"Sato","sequence":"first","affiliation":[{"name":"Department of Pediatrics Jusendo General Hospital Fukushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiko","family":"Kawasaki","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Fukushima Medical University School of Medicine Fukushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Waragai","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Jusendo General Hospital Fukushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Imaizumi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Jusendo General Hospital Fukushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Ono","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Jusendo General Hospital Fukushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuko","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Jusendo General Hospital Fukushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuaki","family":"Hosoya","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Fukushima Medical University School of Medicine Fukushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,6,18]]},"reference":[{"key":"e_1_2_4_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(74)91880-7"},{"key":"e_1_2_4_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-006-0026-5"},{"key":"e_1_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI17423"},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-006-0340-0"},{"key":"e_1_2_4_6_1","doi-asserted-by":"publisher","DOI":"10.1159\/000321630"},{"key":"e_1_2_4_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0707330"},{"key":"e_1_2_4_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfg372"},{"key":"e_1_2_4_9_1","doi-asserted-by":"publisher","DOI":"10.5301\/ejo.5000074"},{"key":"e_1_2_4_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3182278ab4"},{"key":"e_1_2_4_11_1","first-page":"697","article-title":"Pharmacokinetics of intravitreal bevacizumab (Avastin\u00ae) in rabbits","volume":"5","author":"Sinapis CI","year":"2001","journal-title":"Clin. Ophthalmol."},{"key":"e_1_2_4_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2008.156810"},{"key":"e_1_2_4_13_1","doi-asserted-by":"publisher","DOI":"10.5603\/FHC.2011.0067"}],"container-title":["Pediatrics International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fped.12017","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ped.12017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T18:56:52Z","timestamp":1697309812000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ped.12017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["10.1111\/ped.12017"],"URL":"https:\/\/doi.org\/10.1111\/ped.12017","archive":["Portico"],"relation":{},"ISSN":["1328-8067","1442-200X"],"issn-type":[{"value":"1328-8067","type":"print"},{"value":"1442-200X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}